National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.

[1]  Stephanie J. Lee,et al.  The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. , 2021, Transplantation and cellular therapy.

[2]  F. Locatelli,et al.  Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study , 2020 .

[3]  Stephanie J. Lee,et al.  Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213) , 2020, Transplantation and Cellular Therapy.

[4]  D. Venzon,et al.  A randomized phase-2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease. , 2020, Blood.

[5]  G. Socié,et al.  The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. , 2020, Blood advances.

[6]  R. Jenq,et al.  Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. , 2020, Blood.

[7]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[8]  N. Kröger,et al.  Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. , 2020, The Lancet. Haematology.

[9]  Herman Goossens,et al.  Adaptive platform trials: definition, design, conduct and reporting considerations , 2019, Nature Reviews Drug Discovery.

[10]  Heidi Chen,et al.  Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. , 2019, Blood advances.

[11]  J. Chewning,et al.  Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria. , 2019, Blood.

[12]  A. Logan,et al.  Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  K. Sullivan,et al.  How I treat refractory chronic graft-versus-host disease. , 2019, Blood.

[14]  M. Norkin,et al.  Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. Horowitz,et al.  Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. , 2019, JAMA oncology.

[16]  B. Blazar,et al.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. , 2018, Blood advances.

[17]  M. Horowitz,et al.  A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801 , 2018, Haematologica.

[18]  E. Holler,et al.  EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment , 2018, Bone Marrow Transplantation.

[19]  Lisa V. Hampson,et al.  Adaptive designs in clinical trials: why use them, and how to run and report them , 2018, BMC Medicine.

[20]  D. Couriel,et al.  Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  B. Blazar,et al.  Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.

[22]  A. Logan,et al.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. , 2017, Blood.

[23]  B. Storer,et al.  An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. , 2017, Blood.

[24]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[25]  I. Marschner,et al.  Design of clinical trials involving multiple hypothesis tests with a common control , 2017, Biometrical journal. Biometrische Zeitschrift.

[26]  A. Im,et al.  Novel targets in the treatment of chronic graft-versus-host disease , 2017, Leukemia.

[27]  J. Ritz,et al.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  J. Ritz,et al.  Mechanistic approaches for the prevention and treatment of chronic GVHD. , 2017, Blood.

[29]  M. Mohty,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .

[31]  D. Miklos,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  J. Ritz,et al.  Current issues in chronic graft-versus-host disease. , 2014, Blood.

[34]  B. Sandmaier,et al.  Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. , 2014, Blood.

[35]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[36]  J. Scarisbrick,et al.  Diagnosis and management of chronic graft‐versus‐host disease , 2012, British journal of haematology.

[37]  S. Grupp,et al.  Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  H. Salmasian,et al.  Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation. , 2010, The Cochrane database of systematic reviews.

[39]  J. Fay,et al.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. , 2009, Blood.

[40]  James Ferrara,et al.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[43]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[45]  H. Deeg,et al.  Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation , 2005 .